{"id":"W4403251505","doi":"10.1016/j.ygyno.2024.07.092","title":"Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as a firstline treatment for endometrial cancer: Overall survival and additional secondary efficacy en‑dpoints by mismatch repair status in the DUO-E/GOG-3041/ENGOT-EN10 Trial","year":2024,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Durvalumab; Olaparib; Carboplatin; Endometrial cancer; Oncology; Paclitaxel; Internal medicine; Overall survival; Urology; Cancer; Chemotherapy; Cisplatin; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001181012,0.0007557793,0.001602442,0.0002349187,0.0001610157,0.0008531697,0.0004465543,0.0005782499,0.002703285],"category_scores_gemma":[0.0008646445,0.0002536565,0.001685767,0.0002454649,0.0003862976,0.0007128454,0.0002896465,0.00208455,0.0003842067],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009699396,"about_ca_system_score_gemma":0.0007143442,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001409999,"about_ca_topic_score_gemma":0.007657793,"domain_scores_codex":[0.9996558,0.0001793624,0.000015524,0.00005619991,0.0000265298,0.00006653181],"domain_scores_gemma":[0.9996804,0.00009590607,0.00005728102,0.00003469508,0.00001413757,0.0001174996],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8263507,0.003177872,0.005863669,0.001565034,0.007067294,0.0001424874,0.0001206699,0.002805637,0.006787703,0.0006858197,0.00482456,0.1406086],"study_design_scores_gemma":[0.7966439,0.1236261,0.04335652,0.0004807434,0.01139941,0.000543018,0.0002433613,0.005091181,0.004375893,0.001971256,0.01217968,0.00008899993],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9781928,0.01455394,0.0004350473,0.0008232103,0.0004335968,0.000258753,0.001272213,0.00007469876,0.003955759],"genre_scores_gemma":[0.9895773,0.004248091,0.0006055678,0.0009073213,0.0001512912,0.0001805879,0.001507381,0.00002061546,0.002801931],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002703285,"threshold_uncertainty_score":0.009043396,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03717994450346522,"score_gpt":0.3580948638255997,"score_spread":0.3209149193221345,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}